HURA TuHURA Biosciences | $2.47
-5.4% | 6/23/2025 | Upgraded by | Brookline Capital Management | Analyst K. Raja | Strong-Buy | | High | View details for Brookline Capital Management rating of TuHURA Biosciences (NASDAQ:HURA) on 6/23/2025 |
BIVI BioVie | $0.96
-0.9% | 3/18/2025 | Upgraded by | Brookline Capital Management | Analyst T. Bussian | Strong-Buy | | High | View details for Brookline Capital Management rating of BioVie (NASDAQ:BIVI) on 3/18/2025 |
CRVO CervoMed | $5.72
+2.9% | 3/11/2025 | Upgraded by | Brookline Capital Management | Analyst T. Bussian | Hold -> Strong-Buy | | Low | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 3/11/2025 |
CATX Perspective Therapeutics | $3.60
+6.2% | 3/10/2025 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Strong-Buy | | Low | View details for Brookline Capital Management rating of Perspective Therapeutics (NYSE:CATX) on 3/10/2025 |
IMAB I-Mab | $2.23
-2.6% | 2/27/2025 | Upgraded by | Brookline Capital Management | Analyst K. Raja | Strong-Buy | | Low | View details for Brookline Capital Management rating of I-Mab (NASDAQ:IMAB) on 2/27/2025 |
MRKR MARKER THERAPEUTICS | $1.58
+0.4% | 2/10/2025 | Upgraded by | Brookline Capital Management | Analyst L. Cann | Strong-Buy | | Medium | View details for Brookline Capital Management rating of MARKER THERAPEUTICS (NASDAQ:MRKR) on 2/10/2025 |
CGTX Cognition Therapeutics | $0.45
+35.4% | 1/27/2025 | Upgraded by | Brookline Capital Management | Analyst T. Bussian | Strong-Buy | | High | View details for Brookline Capital Management rating of Cognition Therapeutics (NASDAQ:CGTX) on 1/27/2025 |
MDCX Medicus Pharma | $3.38
+5.0% | 12/23/2024 | Upgraded by | Brookline Capital Management | Analyst K. Raja | Strong-Buy | | N/A | View details for Brookline Capital Management rating of Medicus Pharma (NASDAQ:MDCX) on 12/23/2024 |
EXEL Exelixis | $45.91
+3.6% | 12/23/2024 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | | N/A | View details for Brookline Capital Management rating of Exelixis (NASDAQ:EXEL) on 12/23/2024 |
QNCX Quince Therapeutics | $1.61
+0.3% | 12/18/2024 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $9.00 | N/A | View details for Brookline Capital Management rating of Quince Therapeutics (NASDAQ:QNCX) on 12/18/2024 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
CRVO CervoMed | $5.72
+2.9% | 12/10/2024 | Downgraded by | Brookline Capital Management | Analyst T. Bussian | Strong-Buy -> Hold | | N/A | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 12/10/2024 |
YMAB Y-mAbs Therapeutics | $4.31
+1.1% | 12/4/2024 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Strong-Buy | | N/A | View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/4/2024 |
YMAB Y-mAbs Therapeutics | $4.31
+1.1% | 12/5/2024 | Initiated by | Brookline Capital Management | - | Buy | $17.00 | N/A | View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/5/2024 |
EYEN Eyenovia | $15.96
+51.1% | 11/15/2024 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | View details for Brookline Capital Management rating of Eyenovia (NASDAQ:EYEN) on 11/15/2024 |
COCH Envoy Medical | $1.58
+5.4% | 10/14/2024 | Initiated by | Brookline Capital Management | Analyst T. Bussian | Buy | $9.00 | Low | View details for Brookline Capital Management rating of Envoy Medical (NASDAQ:COCH) on 10/14/2024 |
VRCA Verrica Pharmaceuticals | $0.69
+6.1% | 10/2/2024 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | High | View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 10/2/2024 |
OSTX OS Therapies | $1.87
-2.1% | 8/22/2024 | Upgraded by | Brookline Capital Management | Analyst K. Raja | Strong-Buy | | Low | View details for Brookline Capital Management rating of OS Therapies (NYSE:OSTX) on 8/22/2024 |
MEIP MEI Pharma | $2.84
+18.1% | 7/22/2024 | Downgraded by | Brookline Capital Management | Analyst L. Cann | Strong-Buy -> Hold | | Low | View details for Brookline Capital Management rating of MEI Pharma (NASDAQ:MEIP) on 7/22/2024 |
IBIO iBio | $0.73
-1.6% | 7/22/2024 | Initiated by | Brookline Capital Management | Analyst K. Dolliver | Buy | $3.60 | Low | View details for Brookline Capital Management rating of iBio (NYSE:IBIO) on 7/22/2024 |
UNCY Unicycive Therapeutics | $4.64
-0.1% | 7/9/2024 | Upgraded by | Brookline Capital Management | Analyst K. Raja | Strong-Buy | | Low | View details for Brookline Capital Management rating of Unicycive Therapeutics (NASDAQ:UNCY) on 7/9/2024 |
CRVO CervoMed | $5.72
+2.9% | 7/8/2024 | Initiated by | Brookline Capital Management | Analyst T. Bussian | Buy | $63.00 | Low | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 7/8/2024 |
SABS SAB Biotherapeutics | $1.73
-1.1% | 6/7/2024 | Initiated by | Brookline Capital Management | - | Buy | $8.00 | Low | View details for Brookline Capital Management rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/7/2024 |
FBRX Forte Biosciences | $13.81
-0.2% | 5/30/2024 | Initiated by | Brookline Capital Management | - | Buy | $4.00 | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 5/30/2024 |
DARE Dare Bioscience | $2.40
| 5/15/2024 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | $36.00 | Low | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 5/15/2024 |
DARE Dare Bioscience | $2.40
| 4/17/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 4/17/2024 |
IMUX Immunic | $0.73
+2.2% | 4/5/2024 | Reiterated by | Brookline Capital Management | Analyst T. Bussian | Buy | $10.00 | Low | View details for Brookline Capital Management rating of Immunic (NASDAQ:IMUX) on 4/5/2024 |
ATBPF Antibe Therapeutics | $0.22
| 3/4/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 3/4/2024 |
ANVS Annovis Bio | $2.39
+0.2% | 2/28/2024 | Downgraded by | Brookline Capital Management | Analyst T. Bussian | Buy -> Hold | $9.00 | Low | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 2/28/2024 |
OTLK Oncobiologics | $1.81
+5.8% | 1/25/2024 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | $31.40 | Low | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 1/25/2024 |
LNTH Lantheus | $79.21
-0.5% | 11/30/2023 | Initiated by | Brookline Capital Management | - | Buy | $100.00 | Low | View details for Brookline Capital Management rating of Lantheus (NASDAQ:LNTH) on 11/30/2023 |
ANVS Annovis Bio | $2.39
+0.2% | 11/10/2023 | Reiterated by | Brookline Capital Management | Analyst T. Bussian | Buy | $35.00 | Low | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 11/10/2023 |
GNLX Genelux | $2.98
+4.9% | 10/30/2023 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | | Low | View details for Brookline Capital Management rating of Genelux (NASDAQ:GNLX) on 10/30/2023 |
EYEN Eyenovia | $15.96
+51.1% | 10/17/2023 | Initiated by | Brookline Capital Management | - | Buy | $640.00 | Low | View details for Brookline Capital Management rating of Eyenovia (NASDAQ:EYEN) on 10/17/2023 |
EDSA Edesa Biotech | $2.13
+4.4% | 10/12/2023 | Reiterated by | Brookline Capital Management | - | Buy -> Buy | $57.00 | Low | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/12/2023 |
PROC Procaps Group | $0.95
-40.3% | 9/6/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | $4.50 | Low | View details for Brookline Capital Management rating of Procaps Group (NASDAQ:PROC) on 9/6/2023 |
OTLK Oncobiologics | $1.81
+5.8% | 8/30/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 8/30/2023 |
ATBPF Antibe Therapeutics | $0.22
| 8/14/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 8/14/2023 |
DARE Dare Bioscience | $2.40
| 2/14/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 2/14/2023 |
ECOR electroCore | $6.03
+12.5% | 1/12/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 1/12/2023 |
IMNN Imunon | $0.79
-1.1% | 11/14/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 11/14/2022 |
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off (Ad) Right now, we’re witnessing a monumental shift in the world. Our No. 1 AI Pick is currently trading for pennies on the dollar compared to Nividia. |
VXRT VAXART | $0.43
-1.4% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of VAXART (NASDAQ:VXRT) on 10/3/2022 |
OTLK Oncobiologics | $1.81
+5.8% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 10/3/2022 |
MNPR Monopar Therapeutics | $35.87
+2.0% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/3/2022 |
LSTA Lisata Therapeutics | $2.64
-3.3% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 10/3/2022 |
IMNN Imunon | $0.79
-1.1% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 10/3/2022 |
EDSA Edesa Biotech | $2.13
+4.4% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/3/2022 |
ARCT Arcturus Therapeutics | $13.64
+0.1% | 8/10/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/10/2022 |
ATBPF Antibe Therapeutics | $0.22
| 6/30/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/30/2022 |
VERU Veru | $0.60
+2.8% | 5/18/2022 | Target Raised by | Brookline Capital Management | Analyst Kumaraguru Raja | Buy -> Buy | $29.00 -> $31.00 | Medium | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 5/18/2022 |
VRCA Verrica Pharmaceuticals | $0.69
+6.1% | 3/10/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 3/10/2022 |
NTLA Intellia Therapeutics | $10.72
-0.1% | 3/7/2022 | Upgraded by | Brookline Capital Management | Analyst L. Cann | Hold -> Buy | $91.00 | High | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 3/7/2022 |
CRSP CRISPR Therapeutics | $52.16
+0.9% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst Leah Rush | Buy | $143.00 | High | View details for Brookline Capital Management rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/14/2022 |
NTLA Intellia Therapeutics | $10.72
-0.1% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst Leah Rush | Buy | | Low | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/14/2022 |
CRBU Caribou Biosciences | $1.36
-0.7% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Medium | View details for Brookline Capital Management rating of Caribou Biosciences (NASDAQ:CRBU) on 2/14/2022 |
BCDA BioCardia | $2.11
+1.4% | 2/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 2/3/2022 |
ICCM IceCure Medical | $1.06
+4.9% | 2/1/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of IceCure Medical (NASDAQ:ICCM) on 2/1/2022 |
DARE Dare Bioscience | $2.40
| 1/19/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 1/19/2022 |
PROC Procaps Group | $0.95
-40.3% | 12/14/2021 | Reiterated by | Brookline Capital Management | Analyst Kemp Dolliver | Buy | $13.00 | Low | View details for Brookline Capital Management rating of Procaps Group (NASDAQ:PROC) on 12/14/2021 |
KYMR Kymera Therapeutics | $44.81
+0.6% | 10/13/2021 | Reiterated by | Brookline Capital Management | Analyst Leah Rush Cann | Buy | $80.00 | Medium | View details for Brookline Capital Management rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/13/2021 |
FBRX Forte Biosciences | $13.81
-0.2% | 9/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Hold | | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 9/3/2021 |
VERU Veru | $0.60
+2.8% | 8/27/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/27/2021 |
SCYX SCYNEXIS | $0.73
+1.5% | 8/24/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/24/2021 |
CCCC C4 Therapeutics | $1.49
-2.0% | 6/25/2021 | Reiterated by | Brookline Capital Management | Analyst Leah Rush Cann | Buy | | High | View details for Brookline Capital Management rating of C4 Therapeutics (NASDAQ:CCCC) on 6/25/2021 |
ATBPF Antibe Therapeutics | $0.22
| 6/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/3/2021 |
MNPR Monopar Therapeutics | $35.87
+2.0% | 5/25/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 5/25/2021 |
BIOX Bioceres Crop Solutions | $4.72
-5.4% | 5/7/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 5/7/2021 |
MRNA Moderna | $30.47
+0.6% | 2/26/2021 | Target Raised by | Brookline Capital Management | - | Buy | $180.00 -> $205.00 | Low | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 2/26/2021 |
XFOR X4 Pharmaceuticals | $1.97
-0.8% | 12/17/2020 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | $630.00 | High | View details for Brookline Capital Management rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 12/17/2020 |
VERU Veru | $0.60
+2.8% | 12/14/2020 | Target Raised by | Brookline Capital Management | Analyst K. Raja | | $13.00 -> $17.00 | High | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 12/14/2020 |
ECOR electroCore | $6.03
+12.5% | 10/23/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $75.00 | Low | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 10/23/2020 |
MEIP MEI Pharma | $2.84
+18.1% | 10/12/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Medium | View details for Brookline Capital Management rating of MEI Pharma (NASDAQ:MEIP) on 10/12/2020 |
FBRX Forte Biosciences | $13.81
-0.2% | 8/28/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $90.00 | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 8/28/2020 |
KURA Kura Oncology | $5.91
+1.7% | 8/16/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Low | View details for Brookline Capital Management rating of Kura Oncology (NASDAQ:KURA) on 8/16/2020 |
VERU Veru | $0.60
+2.8% | 8/14/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/14/2020 |
ARCT Arcturus Therapeutics | $13.64
+0.1% | 8/11/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/11/2020 |
MRNA Moderna | $30.47
+0.6% | 7/13/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | $95.00 | High | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 7/13/2020 |
ASRT Assertio | $0.68
+0.9% | 6/3/2020 | Initiated by | Brookline Capital Management | - | Buy | $3.50 | Low | View details for Brookline Capital Management rating of Assertio (NASDAQ:ASRT) on 6/3/2020 |
OTLK Oncobiologics | $1.81
+5.8% | 5/5/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 5/5/2020 |
DARE Dare Bioscience | $2.40
| 4/28/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $90.00 | High | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 4/28/2020 |
EDSA Edesa Biotech | $2.13
+4.4% | 3/30/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $70.00 | High | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 3/30/2020 |
CLPT ClearPoint Neuro | $11.85
+5.0% | 3/11/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/11/2020 |
ARMP Armata Pharmaceuticals | $2.17
+11.9% | 3/13/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) on 3/13/2020 |
CLPT ClearPoint Neuro | $11.85
+5.0% | 3/12/2020 | Initiated by | Brookline Capital Management | - | Buy | $15.00 | N/A | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/12/2020 |
MNPR Monopar Therapeutics | $35.87
+2.0% | 2/19/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $210.00 | High | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 2/19/2020 |
BIOX Bioceres Crop Solutions | $4.72
-5.4% | 2/4/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | N/A | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 2/4/2020 |
BCDA BioCardia | $2.11
+1.4% | 11/26/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019 |
BCDA BioCardia | $2.11
+1.4% | 11/26/2019 | Initiated by | Brookline Capital Management | - | Buy | $330.00 | Low | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019 |
MDNA Medicenna Therapeutics | C$0.91
+1.1% | 11/19/2019 | Reiterated by | Brookline Capital Management | - | Buy | C$4.00 | N/A | View details for Brookline Capital Management rating of Medicenna Therapeutics (TSE:MDNA) on 11/19/2019 |
SCYX SCYNEXIS | $0.73
+1.5% | 8/19/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/19/2019 |
VXRT VAXART | $0.43
-1.4% | 8/15/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $6.00 | Low | View details for Brookline Capital Management rating of VAXART (NASDAQ:VXRT) on 8/15/2019 |
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off (Ad) Right now, we’re witnessing a monumental shift in the world. Our No. 1 AI Pick is currently trading for pennies on the dollar compared to Nividia. |
VERU Veru | $0.60
+2.8% | 7/29/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $12.00 | High | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 7/29/2019 |
ARCT Arcturus Therapeutics | $13.64
+0.1% | 7/24/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 7/24/2019 |
SCYX SCYNEXIS | $0.73
+1.5% | 1/4/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 1/4/2019 |
ARCT Arcturus Therapeutics | $13.64
+0.1% | 9/27/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/27/2018 |
TNXP Tonix Pharmaceuticals | $35.50
+0.9% | 7/27/2018 | Downgraded by | Brookline Capital Management | Analyst K. Raja | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 7/27/2018 |
TNXP Tonix Pharmaceuticals | $35.50
+0.9% | 5/1/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 5/1/2018 |
